CAS 2152628-33-4
:LOXO-292
Description:
LOXO-292, also known as Selpercatinib, is a selective inhibitor of the RET (rearranged during transfection) kinase, which plays a crucial role in various cellular processes, including cell growth and differentiation. This compound is primarily utilized in the treatment of certain types of cancers, particularly those with RET gene alterations, such as non-small cell lung cancer and thyroid cancer. LOXO-292 exhibits high specificity for RET, minimizing off-target effects and enhancing its therapeutic efficacy. The substance is characterized by its oral bioavailability, allowing for convenient administration. Its mechanism of action involves the inhibition of RET signaling pathways, leading to reduced tumor cell proliferation and survival. Clinical studies have demonstrated its effectiveness in patients with RET fusion-positive tumors, showcasing a favorable safety profile. As a targeted therapy, LOXO-292 represents a significant advancement in personalized medicine, offering hope for improved outcomes in patients with specific genetic mutations associated with cancer.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
(piperidin-4-yl)urea hydrochloride
CAS:Formula:C29H31N7O3Purity:98%Color and Shape:SolidMolecular weight:525.6015Selpercatinib
CAS:"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."Formula:C29H31N7O3Purity:99.89% - >99.99%Color and Shape:SolidMolecular weight:525.6Selpercatinib-D₃
CAS:Controlled ProductFormula:C29D3H28N7O3Color and Shape:NeatMolecular weight:528.62
